Pulmonary Fibrosis News and Research

RSS
La Jolla acquires GliaMed's novel class of compounds

La Jolla acquires GliaMed's novel class of compounds

MicroRNAs may play a key role in future medicine

MicroRNAs may play a key role in future medicine

CPF applauds new guidelines for treatment of idiopathic pulmonary fibrosis

CPF applauds new guidelines for treatment of idiopathic pulmonary fibrosis

EC grants marketing authorization for InterMune's Esbriet to treat IPF

EC grants marketing authorization for InterMune's Esbriet to treat IPF

Acute viral infection does not appear to cause exacerbation of IPF

Acute viral infection does not appear to cause exacerbation of IPF

Single donor gifts lungs for two lung transplants

Single donor gifts lungs for two lung transplants

Registration open for idiopathic pulmonary fibrosis healthcare summit

Registration open for idiopathic pulmonary fibrosis healthcare summit

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

KineMed's fibrosis research program featured in Nature Medicine

KineMed's fibrosis research program featured in Nature Medicine

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

Gilead to acquire Arresto

Gilead to acquire Arresto

InterMune's MAA for Esbriet receives positive CHMP opinion

InterMune's MAA for Esbriet receives positive CHMP opinion

RXi's dermal anti-scarring candidate selected to advance into development

RXi's dermal anti-scarring candidate selected to advance into development

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Marker for aggressive form of idiopathic pulmonary fibrosis discovered

Marker for aggressive form of idiopathic pulmonary fibrosis discovered

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.